Shan Fu, M.A.
Managing Partner

Shan Fu joined Vivo in 2013 as a Managing Partner, Co-CEO and CEO of Asia Pacific. Before joining Vivo, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China’s National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China.

Mr. Fu serves on the boards of a number of public and private healthcare companies. Currently, he serves as Chairman of the Board at TOT Biopharm (SEHK:1875) and Evaheart. He also serves on the boards of Sinovac Biotech, Lepu Scientech (SEHK:2291), Caidya, New Frontier Health, Esco Lifesciences Group and Visen Pharmaceuticals.

Mr. Fu received a Bachelor’s and Master’s Degree in History from Peking University in Beijing, China.